Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03803618
Other study ID # UPM REB 2017-0237
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 1, 2017
Est. completion date April 30, 2023

Study information

Verified date May 2023
Source University of the Philippines
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is an observational study that aims to determine the effectiveness of a tetravalent dengue vaccine (CYD-TDV) when given through a community-based immunization program against hospitalized and /or severe virologically confirmed dengue.


Description:

This is a matched case-control study. Cases will be children who are admitted with a clinical suspicion of dengue at the study hospitals and were eligible to have received the dengue vaccine during the mass immunization. The outcome of interest is hospitalized and/or severe virologically-confirmed dengue and the exposure is receipt of the dengue vaccine. Each case will be matched to two controls who were also eligible to have received the dengue vaccine and lives in the same area as the case. Cases and controls will be matched by age and sex.


Recruitment information / eligibility

Status Completed
Enrollment 2081
Est. completion date April 30, 2023
Est. primary completion date November 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 9 Years to 14 Years
Eligibility Inclusion Criteria: CASE-CONTROL STUDIES - For a suspected case to be enrolled in the study, he/she should: - Provide signed informed consent and assent (as applicable) - Be within the age group eligible to receive the dengue vaccine at the time of mass vaccination (i.e. no condition that would have made him/her ineligible for dengue vaccination) - Be admitted in any of the participating hospitals for suspected dengue - Have =5 days history of fever. - For the case to be included in the analysis, the participant must meet all the inclusion criteria above plus have virologically-confirmed dengue infection by RT-PCR - For controls to be recruited into the study, he/she should: - Provide signed informed consent and assent (as applicable) - Be age and sex-matched to the case - Be from the same community as the matched case - Be eligible to have received dengue vaccine during the community-based dengue immunization campaign in 2017 (i.e. no condition that would have made him/her ineligible for dengue vaccination) - Have had no episode of clinically-diagnosed or laboratory-confirmed dengue fever from the start of the community -based dengue immunization campaign to the focal time (the date of onset of dengue fever in the matched case) - Should not have been previously recruited as a control. Exclusion Criteria: • Any subject whose parent/guardian refuse to provide informed consent and/or assent. - In addition, the following conditions automatically exclude children from the dengue mass immunization: - Children <9 years or adults older than 45 years of age - Anyone who is allergic or has had an allergic reaction to a prior dose or to any component of the dengue vaccine - Recipient of blood product in the last 3 months - Immunocompromised individuals, due to but not limited to genetic defects, HIV infection, or therapies that affect the immune system such as high-dose corticosteroids or chemotherapy - Recipient of any vaccine within the past month - History of bleeding disorder - Pregnant or breastfeeding women - Enrolled in dengue vaccine Phase 3 clinical study

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Philippines Cebu Provincial Hospital - Balamban Balamban Cebu
Philippines Cebu Provincial Hospital - Bogo Bogo City Cebu
Philippines Cebu Provincial Hospital - Danao Danao Cebu
Philippines Eversley Childs Sanitarium and General Hospital Mandaue City Cebu

Sponsors (3)

Lead Sponsor Collaborator
University of the Philippines Research Institute for Tropical Medicine, Philippines, Sanofi Pasteur, a Sanofi Company

Country where clinical trial is conducted

Philippines, 

Outcome

Type Measure Description Time frame Safety issue
Primary hospitalized and / or severe virologically confirmed dengue The primary outcome are children who are hospitalized and/or severe virologically confirmed dengue 5 years
See also
  Status Clinical Trial Phase
Completed NCT05321264 - Educational Intervention to Promote Control Behaviors and Prevention of Dengue N/A
Completed NCT01436396 - Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Phase 3
Completed NCT01391819 - Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children N/A
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT02833584 - Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults N/A
Completed NCT02433652 - Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2 Phase 1
Enrolling by invitation NCT02016027 - Pharmacological Effect of Carica Papaya Leaves Mother Tincture in Healthy Individuals Blood Parameter Phase 1
Completed NCT01477671 - Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children N/A
Recruiting NCT00377754 - Prospective Study of Infant Dengue N/A
Recruiting NCT05919277 - A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires
Recruiting NCT04582474 - Demonstration of an Electronic Clinical Decision Support Module for Dengue in Burkina Faso N/A
Completed NCT01983553 - Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
Active, not recruiting NCT05967455 - Homologous Re-infection With Dengue 1 or Dengue 3 Phase 1
Completed NCT03631719 - Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
Recruiting NCT02606019 - The Use of Biomarkers in Predicting Dengue Outcome N/A
Completed NCT02372175 - Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain Phase 1
Active, not recruiting NCT01696422 - Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine Phase 2
Completed NCT00993447 - Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Phase 2
Completed NCT00375726 - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults Phase 1
Completed NCT05153018 - Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu N/A